Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

Shares of Hutchmed (China) hit their highest levels in over a month after the company announced along with Innovent Biologics ...

The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

Background Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for ...

Manojkumar Bupathi, MD, MS, discussed his takeaways on physician decision-making for frontline metastatic renal cell carcinoma (RCC) treatment from a Case-Based Roundtable event.

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...

Pharmaceutical Co. Ltd.’s LYN/BTK dual inhibitor, DZD-8586, saw tumor shrinkage in 94.1% of patients with relapsed or ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.